C*VID-19 Jab M*nufacturer *ffers F*nancial *ncentives To *nroll *nfants, Y*ung Ch*ldren *nto Cl*nical Tr*als

According to The Defender, Novavax, an American biotechnology company, is offering parents financial incentives to enroll their children in the vaccine manufacturer’s Phase 2/3 COVID-19 jab trial for children aged six months through 11 years.

The trial, called the “Hummingbird” trial, began Phase 2/3 in 2022.

“The trial will evaluate the